

ASTRAZENECA PLC  
Form 6-K  
December 03, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of December 2018

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue  
Cambridge Biomedical Campus  
Cambridge CB2 0AA  
United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):  
82- \_\_\_\_\_

AstraZeneca PLC

INDEX TO EXHIBITS

1.  
Block listing Interim Review

3 December 2018 16:00 GMT

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 3 December 2018

Name of applicant: ASTRAZENECA PLC

Name of scheme: ASTRAZENECA SHARE OPTION  
PLAN; ASTRAZENECA  
SAVINGS-RELATED SHARE  
OPTION PLAN; ASTRAZENECA  
ALL-EMPLOYEE SHARE PLAN;  
ASTRAZENECA PLC 2012  
SAVINGS-RELATED SHARE  
OPTION SCHEME

Period of return: From: 1 June 2018 To: 30 November 2018

Balance of unallotted  
securities under  
scheme(s) from previous  
return: 1,991,308

Plus: The amount by  
which the block  
scheme(s) has been  
increased since the date 0  
of the last return (if any  
increase has been  
applied for):

Less: Number 164,291  
of securities issued/allotted  
under scheme(s) during

period (see LR3.5.7G):

Equals: Balance under  
scheme(s) not yet  
issued/allotted at end of 1,827,017  
period:

Name of contact: CAMILLA  
WISEMAN

Telephone number of contact: 020 3749 5000

#### About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit [www.astrazeneca.com](http://www.astrazeneca.com) and follow us on Twitter @AstraZeneca.

#### Media Relations

|                  |           |                  |
|------------------|-----------|------------------|
| Karen Birmingham | UK/Global | +44 203 749 5634 |
| Rob Skelding     | UK/Global | +44 203 749 5821 |
| Matt Kent        | UK/Global | +44 203 749 5906 |
| Gonzalo Viña     | UK/Global | +44 203 749 5916 |
| Jennifer Hursit  | UK/Global | +44 7384 799 726 |
| Jacob Lund       | Sweden    | +46 8 553 260 20 |
| Michele Meixell  | US        | +1 302 885 2677  |

#### Investor Relations

|                     |                            |                  |
|---------------------|----------------------------|------------------|
| Thomas Kudsk Larsen |                            | +44 203 749 5712 |
| Henry Wheeler       | Oncology                   | +44 203 749 5797 |
| Christer Gruvris    | Cardiovascular; Metabolism | +44 203 749 5711 |
| Nick Stone          | Respiratory; Renal         | +44 203 749 5716 |
| Josie Afolabi       | Other                      | +44 203 749 5631 |
| Craig Marks         | Finance; Fixed Income      | +44 7881 615 764 |
| Jennifer Kretzmann  | Retail Investors           | +44 203 749 5824 |
| US toll-free        |                            | +1 866 381 7277  |

Adrian Kemp  
Company Secretary  
AstraZeneca PLC

SIGNATURES

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 03 December 2018

By: /s/ Adrian Kemp  
Name: Adrian Kemp  
Title: Company Secretary